Recent advances in nanomaterials with inherent optical and magnetic properties for bio-imaging and imaging-guided nucleic acid therapy.
Sign Up to like & getrecommendations! Published in 2020 at "Bioconjugate chemistry"
DOI: 10.1021/acs.bioconjchem.0c00126
Abstract: Nucleic acid therapy is and will continue to be of great interest in cancer treatment. The development of nanocarriers with high nucleic acid loading capacity, low toxicity, and specific targeting, with excellent pharmacokinetic/pharmacodynamic profiles, will… read more here.
Keywords: acid therapy; bio imaging; imaging imaging; acid ... See more keywords
Association between BHMT and CBS gene promoter methylation with the efficacy of folic acid therapy in patients with hyperhomocysteinemia
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Human Genetics"
DOI: 10.1038/s10038-019-0672-7
Abstract: Both betaine homocysteine methyltransferase (BHMT) and cystathionine β-synthase (CBS) are major enzymes in the metabolism of plasma homocysteine (Hcy). Abnormal methylation levels of BHMT and CBS are positively associated with Hcy levels. The present study… read more here.
Keywords: folic acid; methylation; acid therapy; bhmt cbs ... See more keywords
High-dose IV ascorbic acid therapy in CCUS patients with TET2 mutations.
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood.2024024962
Abstract: This was a phase II trial, evaluating the safety/efficacy of high-dose IV-ascorbic acid in patients with TET2 mutant CCUS. Eight of 10 patients enrolled were eligible for response assessment. At week 20, there were no… read more here.
Keywords: acid therapy; patients tet2; high dose; dose ascorbic ... See more keywords
Doubly bi-allelic variants of MTHFR and MTHFD1 in a Chinese patient with hyperhomocysteinemia and failure of folic acid therapy
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Genetics"
DOI: 10.3389/fgene.2022.964990
Abstract: Background: Hyperhomocysteinemia (HHcy) is a risk factor for thromboembolic disease. Defects in one-carbon metabolism (1-CM)-related genes, such as methylenetetrahydrofolate reductase (MTHFR), methylenetetrahydrofolate dehydrogenase, cyclohydrolase, and formyltetrahydrofolate synthetase 1 (MTHFD1), can cause HHcy and may also… read more here.
Keywords: acid therapy; folic acid; failure folic; hhcy ... See more keywords